參考文獻 |
1. World Alzheimer report 2009. Alzheimer’s Disease International.
2. Wimo A, Winblad B, Jönsson L (March 2010) The worldwide societal costs of dementia: Estimates for 2009. Alzheimer’s & Dementia 6: 98-103.
3. Wimo A, Jönsson L, Bond J, Prince M, Winbald B (January 2013) The worldwide economic impact of dementia 2010. Alzheimer’s & Dementia 9: 1-11.e13.
4. Vishal S, Sourabh A, Harkirat S, Sourabh A (February 2011) Alois Alzheimer (1864 - 1915) and the Alzheimer syndrome. Journal of Medical Biography 19: 32-33.
5. Bradley B (December 2006) A review of the non-Alzheimer dementias. The Journal of Clinical Psychiatry 67: 1985-2001.
6. Association As (May 2009) 2009 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia 5: 234-270.
7. Velayudhan L, Poppe M, Archer N, Proitsi P, Brown RG, et al. (2010) Risk of developing dementia in people with diabetes and mild cognitive impairment. The British Journal of Psychiatry 196: 36-40.
8. LG E, RA W, LJ K, GJ B (November 2012) An update on type 2 diabetes, vascular dementia and Alzheimer’s disease. Experimental Gerontology 47: 858 - 864.
9. Hsu C-C, Wahlqvist ML, Lee M-S, Tsai H-N (2011) Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. Journal of Alzheimer’s Disease 24: 485-493.
10. Shaw JE, Sicree RA, Zimmet PZ (January 2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 87: 4-14.
11. Xu WL, Strauss Ev, Qiu CX, Winblad B, Fratiglioni L (June 2009) Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia 52: 1031-1039.
12. Pahan K (May 2006) Lipid-lowering drugs. Cellular and Molecular Life Sciences 63: 1165-1178.
13. Lewington S, Whitlock G, Clarke R (December 2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. The Lancet 370: 1829-1839.
14. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, et al. (January 2013) Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews Issue 1. Art. No.: CD004816. DOI: 10.1002/14651858.CD004816.pub5. .
15. Chiu H-F, Ho S-C, Chen C-C, Yang C-Y (May 2011) Statin use and the risk of liver cancer: A population-based case-control study. The American Journal of Gastroenterology 106: 894-898.
16. Khurana V, Bejjanki HR, Caldito G, Owens MW (2007) Statins reduce the risk of lung cancer in humans: A large case-control study of US Veterans. Chest 131: 1282-1288.
17. Amarenco P, Labreuche J, Lavallée P, Touboul P-J (2004) Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke 35: 2902-2909.
18. Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, et al. (July 2011) Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. The American Journal of Gastroenterology 106: 1340-1350.
19. Fortuny J, Kogevinas M, Zens MS, Schned A, Andrew AS, et al. (10 August 2007) Analgesic and anti-inflammatory drug use and risk of bladder cancer: A population based case control study. BMC Urology 7 doi:10.1186/1471-2490-7-13.
20. Slatore CG, Au DH, Littman AJ, Satia JA, White E (March 2009) Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiology, Biomarkers & Prevention 18: 1203-1207.
21. Colin B, L B, R C, J E, J G, et al. (May 2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849-1860.
22. Norris JW (September 2005) Antiplatelet agents in secondary prevention of stroke: A perspective. Stroke 36: 2034-2036.
23. Zhange P, Zhang X, Brown J, Vistisen D, Sicree R, et al. (March 2010) Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 87: 293-301.
24. Jick H, Zornberg G, DS SJ, Seshadri S, Drachman D (November 2000) Statins and the risk of dementia. The Lancet 356: 1627-1631.
25. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD (July 2008) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71: 344-350.
26. Haag MDM, Hofman A, Koudstaal PJ, Stricker BHC, Breteler MMB (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80: 13-17.
27. Wong WB, Lin VW, Boudreau D, Devine EB (April 2013) Statins in the prevention of dementia and Alzheimer’s disease: A meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiology and Drug Safety 22: 345-358.
28. Song Y, Nie H, Xu Y, Zhang L, Wu Y (March 2013) Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies. Geriatrics & Gerontology International DOI: 10.1111/ggi.12044.
29. Ancelin M-L, Carri`ere I, Barberger-Gateau P, Auriacombe S, Rouaud O, et al. (2012) Lipid lowering agents, cognitive decline, and dementia: the three-city study. 30: 629-637.
30. B. Z, S. T, M. F (2007) Prevention and treatment of dementia or Alzheimer’s disease by statins: A meta-analysis. Dementia and Geriatric Cognitive Disorders 23: 194-201.
31. Thomas T, Nadackal TG, Thomas K (October 2001) Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuropharmacology and Neurotoxicology 12: 3263-3267.
32. Szekely CA, Green RC, Breitner JCS, Ostbye T, Beiser AS, et al. (June 2008) No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70: 2291-2298.
33. Landi F, Cesari M, Onder G, Russo A, Torre S, et al. (April 2003) Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. The American Journal of Geriatric Psychiatry 11: 179-185.
34. Etminan M, Gill S, Samii A (July 2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. British Medical Journal 327: 128-131.
35. Szekely CA, Breitner JCS, Fitzpatrick AL, Rea TD, Psaty BM, et al. (January 2008) NSAID use and dementia risk in the Cardiovascular Health Study. Neurology 70: 17-24.
36. Arvanitakis Z, Grodstein F, Bienias JL, Schneider JA, Wilson RS, et al. (June 2008) Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70: 2219-2225.
37. Cornelius C, Fastbom J, Winblad B, Viitanen M (2004) Aspirin, NSAIDs, risk of dementia, and Influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology 23: 135-143.
38. Chang C-W, Kok VC, Tseng T-C, Horng J-T, Liu C-E (December 2012) Diabetic patients with severe sepsis admitted to intensive care unit do not fare worse than non-diabetic patients: A nationwide population-based cohort study. PLOS ONE 7: e50729.
39. Chang C-H, Lin J-W, Wu L-C, Lai M-S (August 2011) Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: A nationwide case-control study. Journal of Clinical Oncology 29: 3001-3007.
40. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH (January 2010) Dementia incidence continues to increase with age in the oldest old: The 90+ study. Annals of Neurology 67: 114-121.
41. Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, et al. (May 2011) Midlife overweight and obesity increase late-life dementia risk: A population-based twin study. Neurology 76: 1568-1574.
42. Deyo RA, Cherkin DC, Ciol MA (June 1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology 45: 613-619.
43. G L, EB L, JA S, JB S, EC P, et al. (August 2007) Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69: 878-885.
44. M F, Z YP, M RJ, L NN, G L (May 2013) Risk factors for dementia with type 2 diabetes mellitus among elderly people in China. Age Ageing 42: 398-400.
45. ML J, N P, ME K, PE S, JG P, et al. (September 2012) Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimer’s & Dementia 8: 437-444.
46. Reitz C, Tang M-X, Luchsinger J, Mayeux R (May 2004) Relation of plasma lipids to Alzheimer disease and vascular dementia. JAMA Neurology 61: 705-714.
47. Wolozin B, Wang SW, Li N-C, Lee A, Lee TA, et al. (July 2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med 5: doi:10.1186/1741-7015-1185-1120.
48. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, et al. (March 2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease:LEADe. Neurology 74: 956-964.
49. DL S, MN S, DJ C, J L, LJ L, et al. (May 2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62: 753-757. |